Abstract
The Southwest Oncology Group evaluated 51 patients with a histologic diagnosis of metastatic adenocarcinoma and an occult primary tumor. Even though all patients received an extensive diagnostic evaluation, only six (12%) primary sites were found. Thirty-six patients whose primary tumor sites remained occult were randomized to receive either 5-FU or combination chemotherapy (5-FU, doxorubicin, and cyclophosphamide [FAC]). There were no responses in either group. The median survival with 5-FU was 105 days and with FAC was 95 days. Toxicity with FAC was more common and more severe.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / secondary*
-
Cyclophosphamide / administration & dosage*
-
Cyclophosphamide / adverse effects
-
Doxorubicin / administration & dosage*
-
Doxorubicin / adverse effects
-
Drug Evaluation
-
Drug Therapy, Combination
-
Fluorouracil / administration & dosage*
-
Fluorouracil / adverse effects
-
Humans
-
Middle Aged
-
Nausea / chemically induced
-
Neutropenia / chemically induced
-
Prognosis
-
Random Allocation
Substances
-
Doxorubicin
-
Cyclophosphamide
-
Fluorouracil